ipilimumab,nivolumab,durvalumab,vinorelbine,paclitaxel,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['nsclc', 'aegean', 'sclc']
impressive data from #aegean at #aacr23 from dr. john heymach and colleagues. this is the first of several phase iii peri-operative io studies in resectable nsclc combining neoadjuvant chemo-immunotherapy followed by adjuvant immunotherapy. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast #ITYSL #HereWeGo